Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.08 | Change: +$0.05 | %Change: +0.99%
Volume: 24,497 | Day High/Low: 5.17/4.97 | 52 Week High/Low: 10.36/2.50
View modes: 
0 stars

Voltaren Gel sold in 130 countries

Chennai, June 24, 2014: Novartis India, OTC Division, announced the launch of the World’s No.1 topical body pain reliever*, Voltaren® Emulgel®, in India. Voltaren Emulgel is available in more than 130...read more
0 stars

RE:RE:RE:RE:RE:Share price 2016

Some good reading for Monday: http://the-gold-report.blogspot.ca/2015/04/possible-buyout-coming.html http://the-gold-report.blogspot.ca/2015/05/strategic-investor.html A testimonial: http://www...read more
5 stars

RE:RE:RE:RE:Share price 2016

Sales are in USD. Dont forget that there were additional gains of $274,000 in Q1 because of this currency difference. In other words, Nuvo gained about $1.6 million from its product sales in Q1, for a...read more
4.5 stars

RE:Fair Value for P2 ROW

There is no longer any doubt that Pennsaid 2 is an elite drug . Peak sales in the US have an excellent chance of hitting $300 million, given how sales of Voltaren ramped up. Its valuation is also very...read more
5 stars

American Retail Price for Pennsaid

Pennsaid Prices, Coupons and Patient Assistance Programs Pennsaid (diclofenac topical) is a member of the topical non-steroidal anti-inflammatories drug class and is commonly used for Osteoarthritis...read more
5 stars

RE:RE:RE:Share price 2016

I made a very simple calculation of 7% margin gain based on the financials for Q1. Nuvo recorded $1.3M of manufacting margin for the quarter based on 18.1M of sales (as noted by Horizon). That's how I...read more
5 stars

RE:RE:Share price 2016

Very good question, and I may be wrong, but here is how I got that information. We made 2.2 million in the first quarter of 2015 from Pennsaid 2%. It was 31,000 prescriptions not bottles dispensed in...read more
5 stars

Fair Value for P2 ROW

There is no better litmus test of a drugs commercial potential than its sales in the US. With P 2 headed for sales of  upwards to $180 million this year, P2 is fully ensconched as a world class drug,...read more
0 stars

RE:Masters of our Domain

Agreed , C99.... SHOULD BE ON THE BOD !!!!  We need a voice to protect our investment  rate and reply
5 stars

Masters of our Domain

We have a nucleus of long shareholders that was formed just prior to the recent AGM. It is not yet a Force de Frappe but we have sufficient heft that certain interventionist options can be employed...read more
0 stars

RE:Share price 2016

You claim that you " assume we make $71 per bottle".  That sounds incredibly high for manufacturing profit (perhaps you converted dimes to dollars?  LOL).  How did you come up with $71? Regards pdm  rate and reply
5 stars

Share price 2016

Nuvo should be profitable by Q3, at the current Horizon sales of pennsaid 2%. I assume we make $71 per bottle, and at the moment given us doing about 6,000 bottles per week, we are on our way. However...read more
5 stars

Instructive metrics

Horizon has added $3.2 billion US to its market cap since it acquired Actimune (sept)and P2 (oct) last fall. Both were anticipated to be the main drivers of sales growth in 2015 and that has been the...read more
3 stars

Its Coming

Its been rumored that Nuvo will be gone late this year. It might be sooner. Waiting later will be more costly, what with those record sales of P2 and WF10 successfully through its trials. With Bloom...read more
5 stars

Earnings per share

So how is it that a stock that has earnings of  $3.85 a share with huge growth on the horizon  at $5.00?  rate and reply
0 stars

RE:RE:RE:Remarkable sales

Exactly. Such sales will also generate about $20 million or more in annual production sales. Along with $5 million in product sales outside US, we have about $25 million in currrent annual product...read more
0 stars

Valeant To Expand Further in Canada

lobe says Valeant to expand further in Canada 2015-05-22 07:48 ET - In the News   The Globe and Mail reports in its Friday edition Valeant Pharmaceuticals ($285.23) plans to expand its presence...read more
0 stars

RE:RE:RE:RE:New presentation today and new Pennsaid 2% numbers

Horizon will have two more presentations during June as of their news release yesterday. 2015-05-21 10:45 ET - News Release   DUBLIN, IRELAND -- (Marketwired) -- 05/21/15 Horizon Pharma plc...read more
0 stars

Exerpts From Bloom Burton Interview

DM: I cover three specialty pharma companies— Knight Therapeutics Inc. (GUD:TSX; KHTRF:OTCMKTS), Concordia Healthcare Corp. (CXR:TSX) and Tribute Pharmaceuticals Canada Inc. (TRX:TSX.V; TBUFF:OTCQX...read more
0 stars

RE:RE:Remarkable sales

2j3k, That is my thinking exactly. Overtaking Voltaren in the US, which has been in ubiquitous use by consumers for the last few years, clearly shows that Europe sales of P2 can secure profits for...read more